|
ES8502612A1
(es)
|
1983-06-15 |
1985-02-01 |
Schering Ag |
Procedimiento para la preparacion de 13a-alquilgonanos
|
|
DE3321826A1
(de)
|
1983-06-15 |
1984-12-20 |
Schering AG, 1000 Berlin und 4709 Bergkamen |
13(alpha)-alkylgonane, deren herstellung und diese enthaltende pharmazeutische praeparate
|
|
US4780461A
(en)
|
1983-06-15 |
1988-10-25 |
Schering Aktiengesellschaft |
13α-alkyl-gonanes, their production, and pharmaceutical preparations containing same
|
|
US4742000A
(en)
|
1986-05-02 |
1988-05-03 |
University Of Chicago |
Antibody to human progesterone receptor and diagnostic materials and methods
|
|
DE3630030A1
(de)
|
1986-09-01 |
1988-03-03 |
Schering Ag |
13(alpha)-alkylgonan-(delta)(pfeil hoch)9(pfeil hoch)(pfeil hoch)((pfeil hoch)(pfeil hoch)1(pfeil hoch)1(pfeil hoch))(pfeil hoch)-5,10-epoxide
|
|
US4774236A
(en)
|
1986-09-17 |
1988-09-27 |
Research Triangle Institute |
17α-(substituted-methyl)-17β-hydroxy/esterified hydroxy steroids and pharmaceutical compositions containing them
|
|
IE60780B1
(en)
|
1987-01-23 |
1994-08-10 |
Akzo Nv |
New 11-aryl steroid derivatives
|
|
DE3822770A1
(de)
|
1988-07-01 |
1990-01-04 |
Schering Ag |
13-alkyl-11ss-phenylgonane
|
|
US5283190A
(en)
|
1989-07-31 |
1994-02-01 |
Traish Adbulmaged M |
Specific monoclonal antibodies against a defined epitope of progesterone receptor and methods for their use
|
|
DE4008584A1
(de)
|
1990-03-15 |
1991-09-26 |
Schering Ag |
Verfahren zur herstellung von zwischenprodukten fuer die antigestagensynthese (onapristonsynthese)
|
|
US5141961A
(en)
|
1991-06-27 |
1992-08-25 |
Richrdson-Vicks Inc. |
Process for solubilizing difficulty soluble pharmaceutical actives
|
|
MX9301121A
(es)
|
1992-03-02 |
1993-09-01 |
Schering Ag |
Metodo y equipo para la contracepcion oral y regulacion de la menstruacion con estrogeno/progestina/aniprogestina.
|
|
CN1053450C
(zh)
|
1992-11-19 |
2000-06-14 |
北京第三制药厂 |
17位取代11β－取代芳香基－4,9－雌甾二烯类化合物的全合成法
|
|
DE4332283A1
(de)
|
1993-09-20 |
1995-04-13 |
Jenapharm Gmbh |
Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
|
|
FI971742A0
(fi)
*
|
1994-10-24 |
1997-04-23 |
Schering Ag |
Kompetitiivisia progesteroniantagonisteja tarpeen sanelemaan raskaudenehkäisyyn naisilla
|
|
US5759577A
(en)
|
1995-01-17 |
1998-06-02 |
American Home Products Corporation |
Controlled release of steroids from sugar coatings
|
|
US6900193B1
(en)
|
1996-05-01 |
2005-05-31 |
The United States Of America As Represented By The Department Of Health And Human Services |
Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents
|
|
IL122740A
(en)
|
1997-01-15 |
2003-09-17 |
Akzo Nobel Nv |
16-hydroxy-11-(substituted phenyl)-estra-9,4-diene derivatives, their preparation and pharmaceutical compositions containing them
|
|
US5962444A
(en)
|
1998-05-29 |
1999-10-05 |
Research Triangle Institute |
17β-nitro-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
|
|
US6537584B1
(en)
|
1999-11-12 |
2003-03-25 |
Macromed, Inc. |
Polymer blends that swell in an acidic environment and deswell in a basic environment
|
|
AU6469601A
(en)
|
2000-05-19 |
2001-12-03 |
Genentech Inc |
Gene detection assay for improving the likelihood of an effective response to anerbb antagonist cancer therapy
|
|
US6750015B2
(en)
|
2000-06-28 |
2004-06-15 |
Kathryn B. Horwitz |
Progesterone receptor-regulated gene expression and methods related thereto
|
|
UY26966A1
(es)
|
2000-10-18 |
2002-06-20 |
Schering Ag |
Uso de antiprogestinas para la inducción de apoptosis en una célula
|
|
US7381976B2
(en)
|
2001-03-13 |
2008-06-03 |
Triton Thalassic Technologies, Inc. |
Monochromatic fluid treatment systems
|
|
AUPR546801A0
(en)
|
2001-06-05 |
2001-06-28 |
Commonwealth Scientific And Industrial Research Organisation |
Recombinant antibodies
|
|
US7105642B2
(en)
|
2001-08-03 |
2006-09-12 |
Cell Signalling Technology, Inc. |
Monoclonal antibodies specific for phosphorylated estrogen receptor alpha (Ser118) and uses thereof
|
|
US20040121304A1
(en)
|
2001-12-21 |
2004-06-24 |
Ulrike Fuhrmann |
Method for screening for progesterone receptor isoform-specific ligands and for tissue-selective progesterone receptor ligands
|
|
CA2516319C
(en)
|
2003-02-28 |
2012-09-18 |
The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services |
Method for preparing 17.alpha.-acetoxy-11.beta.-(4-n,n-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione, intermediates thereof, and methods for the preparation of such intermediates
|
|
US20040265371A1
(en)
|
2003-06-25 |
2004-12-30 |
Looney Dwayne Lee |
Hemostatic devices and methods of making same
|
|
US7247625B2
(en)
*
|
2003-10-09 |
2007-07-24 |
Wyeth |
6-amino-1,4-dihydro-benzo[d][1,3] oxazin-2-ones and analogs useful as progesterone receptor modulators
|
|
PT1768625E
(pt)
|
2004-07-09 |
2011-04-18 |
Hra Pharma Lab |
Composições de libertação sustida contendo moduladores do receptor da progesterona
|
|
WO2006036726A1
(en)
|
2004-09-22 |
2006-04-06 |
Tripath Imaging, Inc. |
Methods and computer program products for analysis and optimization of marker candidates for cancer prognosis
|
|
WO2006111856A1
(en)
|
2005-04-20 |
2006-10-26 |
Pfizer Limited |
Pyrazole derivatives as progesterone receptor antagonists
|
|
WO2007078599A2
(en)
|
2005-12-16 |
2007-07-12 |
The Board Of Trustees Of The Leland Stanford Junior University |
Functional arrays for high throughput characterization of gene expression regulatory elements
|
|
US20070167971A1
(en)
|
2006-01-17 |
2007-07-19 |
Raymond Huey |
Devices and methods for promoting the formation of blood clots in esophageal varices
|
|
US20070166372A1
(en)
|
2006-01-19 |
2007-07-19 |
Mai De Ltd. |
Preparation of solid coprecipitates of amorphous valsartan
|
|
EP1989217B1
(en)
|
2006-02-17 |
2012-06-27 |
Janssen Pharmaceutica N.V. |
11-phosphorous steroid derivatives useful as progesterone receptor modulators
|
|
DE102006054535A1
(de)
|
2006-11-15 |
2008-05-21 |
Bayer Schering Pharma Aktiengesellschaft |
Progesteronrezeptorantagonisten
|
|
CN101668739A
(zh)
|
2007-04-24 |
2010-03-10 |
帝斯曼知识产权资产管理有限公司 |
用于制造前维生素d的光化学方法
|
|
CA2596204C
(en)
|
2007-08-07 |
2019-02-26 |
Historx, Inc. |
Method and system for determining an optimal dilution of a reagent
|
|
WO2009025759A1
(en)
|
2007-08-17 |
2009-02-26 |
Progenics Pharmaceuticals (Nevada), Inc. |
Tight junction proteins associated with infection and entry of hepatitis c virus (hcv), methods and uses thereof
|
|
HUE027696T2
(en)
*
|
2007-10-12 |
2016-10-28 |
Novartis Ag |
Preparations containing sphingosine-1-phosphate (S1P) receptor modulators
|
|
EP2075246A1
(en)
|
2007-12-27 |
2009-07-01 |
M. J. Institute of Research |
A process for preparation of amorphous form of atorvastatin hemi-calcium salt
|
|
JP2011511011A
(ja)
|
2008-02-05 |
2011-04-07 |
ハーバー バイオサイエンシーズ，インコーポレイテッド |
医薬的固体状態形態
|
|
TW201002736A
(en)
|
2008-04-28 |
2010-01-16 |
Repros Therapeutics Inc |
Compositions and methods for treating progesterone-dependent conditions
|
|
TWI539953B
(zh)
|
2008-04-28 |
2016-07-01 |
瑞波若斯治療學公司 |
用於治療乳癌之組成物和方法
|
|
WO2010110086A1
(ja)
|
2009-03-27 |
2010-09-30 |
株式会社小松製作所 |
作業車両の省燃費制御装置および作業車両の省燃費制御方法
|
|
US9074002B2
(en)
|
2009-04-27 |
2015-07-07 |
Cold Spring Harbor Laboratory |
PTP1B inhibitors
|
|
WO2010141485A1
(en)
|
2009-06-01 |
2010-12-09 |
Samuel Waxman Cancer Research Foundation |
Compositions and methods to induce differentiation and growth inhibition in breast cancer
|
|
PT2454266E
(pt)
|
2009-07-15 |
2013-10-10 |
Cell Therapeutics Inc |
Sal de citrato de 9e-15-(2-pirrolidin-1-il-etoxi)- 7,12,25-trioxa-19,21,24-triaza-tetraciclo- [18.3.1.1(2,5).1(14)18)]hexacosa- 1(24),2,4,9,14,16,18(26),20,22-nonaeno
|
|
US20110293511A1
(en)
*
|
2009-09-29 |
2011-12-01 |
Terrance Grant Johns |
Specific binding proteins and uses thereof
|
|
US8261855B2
(en)
*
|
2009-11-11 |
2012-09-11 |
Flanders Electric, Ltd. |
Methods and systems for drilling boreholes
|
|
WO2011084513A2
(en)
|
2009-12-15 |
2011-07-14 |
Bind Biosciences, Inc. |
Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers
|
|
SG183924A1
(en)
*
|
2010-03-22 |
2012-10-30 |
Repros Therapeutics Inc |
Compositions and methods for non-toxic delivery of antiprogestins
|
|
EP3702460A1
(en)
|
2010-11-12 |
2020-09-02 |
The General Hospital Corporation |
Polycomb-associated non-coding rnas
|
|
EP2651400B2
(en)
|
2010-12-16 |
2023-01-18 |
Amgen (Europe) GmbH |
Controlled release oral dosage forms of poorly soluble drugs and uses thereof
|
|
EP2655621B1
(en)
|
2010-12-20 |
2018-05-23 |
The General Hospital Corporation |
Polycomb-associated non-coding rnas
|
|
US20140079722A1
(en)
|
2011-03-09 |
2014-03-20 |
Centrose, Llc |
Extracellular targeted drug conjugates
|
|
PH12013501837A1
(en)
*
|
2011-03-11 |
2013-11-18 |
Celgene Corp |
Use of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl)piperidine-2,6-dione in treatment of immune-related and inflammatory diseases
|
|
US9618512B2
(en)
|
2011-04-15 |
2017-04-11 |
J-Pharma Co., Ltd. |
Biomarker for breast cancer
|
|
BR112013029212B1
(pt)
|
2011-05-13 |
2020-05-19 |
Ganymed Pharmaceuticals Ag |
anticorpos para o tratamento de câncer expressando claudina-6
|
|
US20130029953A1
(en)
*
|
2011-07-28 |
2013-01-31 |
Klaus Nickisch |
Progesterone antagonists
|
|
CN103957920B
(zh)
|
2011-10-04 |
2018-04-20 |
因维维斯制药公司 |
用于鉴定和治疗抗黄体制剂敏感性肿瘤的方法和系统
|
|
BR112014013709A2
(pt)
|
2011-12-08 |
2017-08-22 |
Fund Sales |
Métodos, composições farmaceuticas, e kits, para tratar cânceres resitentes às antiprogestinas
|
|
US20130338016A1
(en)
|
2012-04-17 |
2013-12-19 |
Vala Sciences, Inc. |
Method For Integrated Pathology Diagnosis And Digital Biomarker Pattern Analysis
|
|
HK1208057A1
(en)
|
2012-04-27 |
2016-02-19 |
Regents Of The University Of Minnesota |
Breast cancer prognosis, prediction of progesterone receptor subtype and prediction of response to antiprogestin treatment based on gene expression
|
|
JP2015529808A
(ja)
|
2012-07-24 |
2015-10-08 |
シーダーズ−サイナイ メディカル センター |
肺癌を有する患者における化学療法に対する耐性を検出するための新規の方法
|
|
WO2014093918A1
(en)
|
2012-12-13 |
2014-06-19 |
Warsaw Orthopedic, Inc. |
Compositions and methods comprising polyethylene glycol and magnesium for treatment of neuronal injury
|
|
CN113201042A
(zh)
|
2013-03-12 |
2021-08-03 |
康泰科思特生物制药公司 |
奥那司酮多晶型形式和使用方法
|
|
US20140363425A1
(en)
|
2013-03-13 |
2014-12-11 |
J. Dinny Graham |
Systems and methods for identifying cancers having activated progesterone receptors
|
|
US9096641B2
(en)
|
2013-06-05 |
2015-08-04 |
Evestra, Inc. |
Imidazolyl progesterone antagonists
|
|
CN103483449A
(zh)
|
2013-08-20 |
2014-01-01 |
东北农业大学 |
两种scFv抗体、其编码基因及其在制备治疗或预防鸡传染性法氏囊病制剂中的应用
|
|
WO2015157343A1
(en)
|
2014-04-08 |
2015-10-15 |
Arno Therapeutics, Inc. |
Systems and methods for identifying progesterone receptor subtypes
|
|
KR20170084086A
(ko)
|
2014-11-17 |
2017-07-19 |
아르노 테라퓨틱스 인코포레이티드 |
오나프리스톤 연장-방출 조성물 및 방법
|
|
US10053485B2
(en)
|
2015-03-23 |
2018-08-21 |
Evestra, Inc. |
Cytotoxic agents that preferentially target leukemia inhibitory factor (LIF) for the treatment of malignancies and as new contraceptive agents
|
|
US10308676B2
(en)
|
2015-09-25 |
2019-06-04 |
Context Biopharma Inc. |
Methods of making onapristone intermediates
|
|
JP2019503353A
(ja)
|
2015-12-15 |
2019-02-07 |
コンテキスト・バイオファーマ・インコーポレイテッド |
非晶質オナプリストン組成物およびそれを作製する方法
|
|
WO2017165315A1
(en)
|
2016-03-21 |
2017-09-28 |
Arno Therapeutics, Inc. |
Onapristone metabolite compositions and methods
|
|
US11597763B2
(en)
|
2016-05-02 |
2023-03-07 |
Tetragenetics, Inc. |
Anti-Kv1.3 antibodies, and methods of production and use thereof
|
|
WO2018067198A1
(en)
|
2016-10-03 |
2018-04-12 |
The Regents Of The University Of California |
Inhibitory antibodies and methods of use thereof
|